Calibre, a London-based HealthTech company, has emerged from stealth after raising €2.8 million (£2.5 million) in pre-seed funding to date. The company has also launched a new proactive health category called Causal Health Navigation.
The round was led by Berlin-based Amino Collective, with participation from Daybreak Ventures, Cocoa Ventures, as well as a group of experienced founders, operators, and medical experts. Notable angel investors include Gousto founder Timo Boldt and N26 co-founder Maximilian Tayenthal.
Alex Weber, co-founder and CEO of Calibre, said, “Over the last years, we have been witnessing a generational shift in how people think about health – from health being the absence of sickness to it being the foundation to live life fully. Left alone by the system, people are now in the era of health guesswork. Calibre is what comes next: a proactive health partner for life that deeply understands your full picture, tells you what’s actually driving your health, and guides you as your health evolves. Our vision is a world where everyone has the health to realise their potential.”
Calibre was founded in 2025 by Alexander Weber (CEO), former Chief Growth Officer at N26; Ben Levy (CTO), former CTO at HealthTech firms Elvie and Manual; and Dr Reinhold Innerhofer (Chief Medical Officer), a physician and sports scientist.
The company’s proactive health membership integrates diagnostics, clinical expertise, and causal AI to help individuals better understand their health and identify precise ways to improve it.
According to the company, despite rising life expectancy, people in the UK now spend around 25% of their lives in poor health. “74% of UK adults believe that establishing good health habits is key to preventing future illness, yet 37% still find it difficult to know what their body actually needs, and are left guessing. Many are turning to AI chatbots for answers, with 230 million people now asking health-related questions on ChatGPT each week,” Calibre mentioned in the press release.
The UK-based startup argues that general-purpose AI tools are not enough to deliver meaningful health outcomes. Instead, its approach focuses on identifying the root drivers of health by linking medical history, daily behaviours, and environmental factors with appropriate diagnostic testing.
The company says it combines a clinician-led model with causal AI to provide members with an evolving view of their health, along with personalised plans aimed at improving daily energy levels and reducing long-term health risks. It claims this approach removes guesswork and offers insights previously accessible mainly to elite athletes and high-net-worth individuals. Calibre is priced from €79.3 (£69) per month.
The company has applied to become a Care Quality Commission-regulated provider in the UK, where clinical services are currently delivered through its partner DocTap, a CQC-registered provider. The UK serves as Calibre’s initial launch market, with international expansion planned thereafter.
